1-3 of 3
Jamie Ketas
Close
Sort by
Journal Articles

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

Jia Ruan, MD, PhD, Morton Coleman, MD, Richard R. Furman, MD, Patricia Glynn, Maureen Joyce, Jamie Ketas, Ken Cheung, PhD, Sarah Church, Tsiporah Shore, MD, Eric Feldman, MD, Sarah Rutherford, Elizabeth Hyjek, MD, PhD, Amy Chadburn, MD, Shahin Rafii, MD, John P. Leonard, MD
Journal: Blood
Blood (2006) 108 (11): 2751.
https://doi.org/10.1182/blood.V108.11.2751.2751
Published: 2006
Journal Articles

Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results.

John P. Leonard, MD, Richard R. Furman, MD, Ying-Kuen K. Cheung, Ph.D, Eric J. Feldman, MD, Hearn J. Cho, M.D, PhD, Julie M. Vose, MD, Gwen Nichols, MD, Patricia W. Glynn, Maureen A. Joyce, Jamie Ketas, Jia Ruan, MD, PhD, John Carew, MD, Ruben Niesvizky, MD, Ann LaCasce, MD, Amy Chadburn, MD, Ethel Cesarman, MD, PhD, Morton Coleman, MD
Journal: Blood
Blood (2005) 106 (11): 491.
https://doi.org/10.1182/blood.V106.11.491.491
Published: 2005
Journal Articles

TOP-M Chemotherapy (Thiotepa, Oncovin [Vincristine], Prednisone, Mitoxantrone) Plus Rituximab for Marginal Zone Lymphoma.

Morton Coleman, M.D., Richard R. Furman, M.D, Ruben Niesvizky, M.D., Michelle Ashe, Lena Mathews, Jennifer Fiore, Jamie Ketas, John P. Leonard
Journal: Blood
Blood (2004) 104 (11): 4600.
https://doi.org/10.1182/blood.V104.11.4600.4600
Published: 2004